

![]() |
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial |
|
Authors | ![]() | |
Published in | Lancet. Infectious diseases. 2015, vol. 15, no. 10, 1156–1166 | |
Abstract | Safe and effective vaccines against Ebola could prevent or control outbreaks. The safe use of replication-competent vaccines requires a careful dose-selection process. We report the first safety and immunogenicity results in volunteers receiving 3 × 10(5) plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein (rVSV-ZEBOV; low-dose vaccinees) compared with 59 volunteers who had received 1 ×10(7) pfu (n=35) or 5 × 10(7) pfu (n=16) of rVSV-ZEBOV (high-dose vaccinees) or placebo (n=8) before a safety-driven study hold. | |
Identifiers | PMID: 26248510 | |
Full text | ||
Structures | ||
Research groups | Centre de vaccinologie et d'immunologie néonatale (177) Epidémiologie clinique (115) Groupe Desmeules Jules (pharmacologie/toxicologie) (567) Groupe Laurent Kaiser (virologie clinique) (668) Mécanisme de l'inflammation articulaire (44) Rôle du CD44 (809) | |
Citation (ISO format) | CSAKI HUTTNER, Angela et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. In: Lancet. Infectious diseases, 2015, vol. 15, n° 10, p. 1156–1166. doi: 10.1016/S1473-3099(15)00154-1 https://archive-ouverte.unige.ch/unige:76362 |